Health Care Resource Use and Costs of Hemophilia A (HA) in French Adult Patients in 2022: A Nationwide Claims Database Analysis
Author(s)
Lebreton A1, Cahoreau V2, Giraud N3, Delienne S4, Fagnani F5, Bouee S6, Cottin J5, Bureau I5, Rudant J7, Reynaud A7, Fahfouhi Y7, Mammar N7, Ben Romdhane H8, Coumert A7, Lilliu H9, Frenzel L10
1CHU Clermont-Ferrand, Clermont-Ferrand, France, 2CHU Bordeaux, Bordeaux cedex, France, 3Association Française des Hémophiles, Paris, France, 4CHU Dijon, Dijon cedex, France, 5CEMKA, Bourg-la-Reine, France, 6CEMKA, BOURG LA REINE, France, 7Pfizer, Paris, France, 8Pfizer, Paris, ile de france, France, 9Inbeeo, London, LON, UK, 10Hôpital Necker, Paris, France
Presentation Documents
OBJECTIVES: There are few data on healthcare resource use and related costs of French HA patients. The aim of this study was to describe these features in French adult HA patients according to severity in 2022.
METHODS: Data related to adult HA patients alive on 1/1/2022 were extracted from the French claims database (SNDS). A control group without HA matched on age, gender and region was randomly selected in the database. Sub-group analyses were performed according to the treatment regimen (on demand or prophylaxis) and the presence of inhibitors. Direct costs were estimated in a societal perspective.
RESULTS: 4,243 adult patients with HA were identified. Mean age was 44 years, 96.8% were males.
Among the patient’s population, 76.1%, 0.6%, 21.0% and 2.3% patients were treated on demand without and with inhibitors and in prophylaxis without and with inhibitors respectively. Compared to controls, patients with HA had more frequently consultations with general practitioners (77.9%/65.7%), hospital specialists (61.3%/25.1%), nurses (67.2%/43.1%), physiotherapists (20.1%/13.0%) and visits to emergency room visits (23.4%/15.7%). They were more frequently treated with analgesics (91.7%/81.0%) and corticosteroids (50.5%/42.5%). The proportion of HA patients hospitalized was higher than controls, overall (27.3% vs 13.6%) and for bleeding (2.2% vs 0.3%) and orthopedic surgery (8.4% vs 3.4%). The mean annual direct medical costs varied according to treatment patterns:- €12,135 for patients treated on demand without inhibitors (€2,113 for controls)
- €132,792 for patients treated on demand with inhibitors (€1,721 for controls)
- €332,782 for patients treated in prophylaxis without inhibitors (€1,155 for controls)
- €449,174 for patients treated in prophylaxis with inhibitors (€1,324 for controls).
CONCLUSIONS: The cost of HA is high, varies greatly with treatment regimen and presence of inhibitors, and is mostly due to the antihemophilic drugs.
Conference/Value in Health Info
Value in Health, Volume 27, Issue 12, S2 (December 2024)
Code
EE665
Topic
Economic Evaluation, Epidemiology & Public Health, Study Approaches
Disease
Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)